The sale of the ophthalmology business alone could earn the company around $5 billion, according to the report. Private equity firms are already studying the business.
Negotiations are ongoing, and if a sale happens it will likely happen in 2023, Bloomberg reported.
In 2019, Novartis spun-off its Alcon eyecare business. In August, it spun-off its generic-drugs unit.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
